News
This page is intended for media, analysts, and investors.
Read the latest Mereo BioPharma news
Together with patient communities, healthcare professionals, commercial partners and with the support of investors, we are constantly making progress on our mission. We are committed to regularly updating our investors, analysts, and the media on this progress. Here you can read the latest Mereo news and learn about events at which we are speaking.
If you would like to get in touch, you will find ways to contact us on this page.
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
London, UK, Solana Beach, California, and Ahmedabad, India – August 11, 2026 – Mereo BioPharma Group plc (Nasdaq: MREO), a clinical-stage biopharmaceutical company focused on rare diseases and Sentynl Therapeutics, Inc., a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited, today announced that they have entered into an option and license agreement for the U.S. commercial and global manufacturing rights to alvelestat for AATD-LD.
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
London, August 11, 2026 – Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the second quarter ended June 30, 2026, and provided an update on recent corporate highlights.
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference 2026
London, June 2, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2026 on Thursday, June 4, 2026, at 9:55 EDT/ 14:55 BST.
Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)
Mereo BioPharma today announced positive data from an interim analysis of an investigator-initiated study of alvelestat in patients with Bronchiolitis Obliterans Syndrome (“BOS”) following hematopoietic stem cell transplantation (“HCT”).
Mereo BioPharma and Cancer Focus Fund Announce Partnership for Phase 1b/2 Study of Etigilimab in Clear Cell Ovarian Cancer
Study to be Conducted at The University of Texas MD Anderson Cancer Center LONDON and REDWOOD CITY, Calif. and HOUSTON, Texas , April 30, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center (“MD Anderson”) to provide funding and clinical expertise to advance promising cancer therapies, today announced a partnership to evaluate Mereo’s lead anti-TIGIT therapeutic antibody candidate, etigilimab, in clear cell ovarian cancer.
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
-- Ultragenyx Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta -- -- Further Strengthened Management Team -- -- OncXerna Global Licensing Agreement for Navicixizumab -- -- Strengthened Balance Sheet through Public and Private Financings and Business Development
Mereo BioPharma and Ultragenyx Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
Mereo BioPharma and Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), today announced a license and collaboration agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).
Mereo BioPharma Provides Update on AIM Delisting and Continued Listing of its ADSs on Nasdaq, and Provides Update on agreements with Silicon Valley Bank and Kreos Capital
LONDON and REDWOOD CITY, Calif. , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today provided a further update with respect to the cancellation of
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
Mereo BioPharma Group plc and Oncologie, Inc. today announced a global license agreement for the development and commercialization of navicixizumab, an anti-DLL4/VEGF bispecific antibody currently being evaluated in an ongoing Phase 1b study in combination with paclitaxel in patients with advanced heavily pretreated ovarian cancer.
Mereo BioPharma Appoints Suba Krishnan, M.D. as Senior Vice President of Clinical Development
LONDON and REDWOOD CITY, Calif. , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointment of Suba Krishnan , M.D.
Mereo BioPharma Announces Interim Financial Results for the Six Months Ended June 30, 2020 and Provides Corporate Update
On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020 Enrolment resumed in Phase 2 study of alvelestat in Alpha-1 Antitrypsin Deficiency and initiated placebo-controlled Phase 1b/2 clinical trial in COVID-19 respiratory disease Partnering discussions continue for
Mereo BioPharma Receives FDA Rare Pediatric Disease Designation for Setrusumab for the Treatment of Osteogenesis Imperfecta
Mereo BioPharma Group a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease designation to setrusumab for the treatment of osteogenesis imperfecta (“OI”).
Mereo BioPharma Announces Initiation of Placebo-Controlled Phase 1b/2 Clinical Trial with Alvelestat in COVID-19 Respiratory Disease
LONDON and REDWOOD CITY, Calif. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the initiation of a Phase 1b/2 placebo-controlled
Mereo BioPharma Strengthens Management Team; Appoints John Lewicki, PhD, as Chief Scientific Officer and Ann Kapoun, PhD, as SVP of Translational Research and Development
LONDON and REDWOOD CITY, Calif. , June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointments of John Lewicki , PhD, as Chief
Mereo BioPharma Announces Financial Results for the Year Ended December 31, 2019
Operational progress, positioned for clinical milestones in oncology and rare diseases LONDON and REDWOOD CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and
